Results 51 to 60 of about 2,114,452 (380)

پایداری و چرخش ارگانی ویروس تیپ o بیماری تب برفکی در خوکچه هندی [PDF]

Archives of Razi Institute, 2010
از آنجایی که خوکچه هندی به عنوان بهترین حیوان آزمایشگاهی حساس به ویروس بیماری تب برفکی مطرح شده است، مقدار یک میلی لیتر از ویروس تب برفکی تیپ O با غلظت TCID50 106-5/106به ناحیه کف پای 10 سر خوکچه هندی (سمت راست) به روش داخل پوستی تزریق شد.
محمد اسلام پناه, همایون مهروانی, محمدحسن حبل الورید, ح. ایزدی, م. ستوده, ف. جیرانی, ف. طالب لو   +6 more
doaj   +1 more source

Overview of vaccines and vaccination [PDF]

Molecular Biotechnology, 2005
Of the 80-plus known infectious agents pathogenic for humans, there are now more than 30 vaccines against 26 mainly viral and bacterial infections and these greatly minimize subsequent disease and prevent death after exposure to those agents. This article describes the nature of the vaccines, from live attenuated agents to subunits, their efficacy and ...
openaire   +4 more sources

HIV: to vaccinate or not to vaccinate? [PDF]

Nature, 1992
"Improbability of effective vaccination against human immunodeficiency virus ...", declares the title of a new paper by Dr Albert Sabin. But three immunologists see flaws in his argument.
Gordon Ada, Arno Müllbacher, Bob Blanden   +2 more
openaire   +2 more sources

Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape

Nature reviews. Immunology, 2021
Where 2020 saw the development and testing of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at an unprecedented pace, the first half of 2021 has seen vaccine rollout in many countries.
J. Tregoning, Katie E. Flight, Sophie Higham, Ziyin Wang, B. F. Pierce   +4 more
semanticscholar   +1 more source

Challenges and opportunities in setting up a phase III vaccine clinical trial in resource limited settings: Experience from Nepal

Human Vaccines & Immunotherapeutics, 2021
Clinical trials are complicated, time-consuming and costly. From the initial screening, informed consent and recruitment of the participants’ to study completion, the sponsor must undertake a wide array of complex and closely monitored operations ...
Tarun Saluja, Bishnu Rath Giri, Shipra Chaudhary, Dipesh Tamrakar, Piush Kanodia, Sonali Palkar, Sridhar Vemula, Suchada Chinaworapong, Bomi Kim, Birendra Prasad Gupta, Sue Kyoung Jo, Sanet Aspinall, Ganesh Kumar Rai, Duncan Steele, Jerome H. Kim, T. Anh Wartel, Sushant Sahastrabuddhe   +16 more
doaj   +1 more source

Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults.

, 2007
Vietnam currently produces an orally administered, bivalent (O1 and O139) killed whole-cell vaccine and is the only country in the world with endemic cholera to use an oral cholera vaccine in public health practice.
Anh, Dang Duc, Attridge, Stephen, Canh, Do Gia, Carbis, Rodney, Clemens, John, Deen, Jacqueline, Han, Seung Hyun, Holmgren, Jan, Long, Phan Thi, Lopez, Anna Lena, Shin, Seong Hye, Son, Nguyen Hong, Thiem, Vu Dinh, von Seidlein, Lorenz   +13 more
core   +1 more source

Evaluation of Microparticulate Ovarian Cancer Vaccine via Transdermal Route of Delivery [PDF]

, 2016
Ovarian cancer is the fifth most commonly occurring malignancy in women, with the highest mortality rate among all the gynecological tumors. Microparticulate vaccine can serve as an immunotherapeutic approach with a promising antigenic delivery system ...
Akalkotkar, Archana, Chablani, Lipika, D\u27Souza, Martin J, Tawde, Suprita A   +3 more
core   +2 more sources

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

New England Journal of Medicine, 2020
Background Testing of vaccine candidates to prevent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an older population is important, since increased incidences of illness and death from coronavirus disease 2019 (Covid-19 ...
E. Anderson, N. Rouphael, A. Widge, L. Jackson, P. Roberts, M. Makhene, J. Chappell, M. Denison, Laura J. Stevens, A. Pruijssers, A. McDermott, B. Flach, Bob C. Lin, N. Doria-Rose, S. O'dell, S. Schmidt, Kizzmekia S. Corbett, P. Swanson, M. Padilla, K. Neuzil, H. Bennett, B. Leav, M. Makowski, J. Albert, Kaitlyn A. Cross, V. Edara, K. Floyd, M. Suthar, David R. Martinez, R. Baric, Wendy L. Buchanan, C. Luke, Varun K. Phadke, C. Rostad, J. Ledgerwood, B. Graham, J. Beigel   +36 more
semanticscholar   +1 more source

Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients.

Journal of the American Medical Association (JAMA), 2021
Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients In contrast to immunocompetent participants in vaccine trials,1,2 a low proportion (17%) of solid organ transplant recipients mounted a positive antibody ...
B. Boyarsky, William Werbel, R. Avery, A. Tobian, A. Massie, D. Segev, J. Garonzik‐Wang   +6 more
semanticscholar   +1 more source

Recombinant MVA-prime elicits neutralizing antibody responses by inducing antigen-specific B cells in the germinal center

npj Vaccines, 2021
The RV144 HIV-1 vaccine trial has been the only clinical trial to date that has shown any degree of efficacy and associated with the presence of vaccine-elicited HIV-1 envelope-specific binding antibody and CD4+ T-cell responses.
Leila Eslamizar, Constantinos Petrovas, David J. Leggat, Kathryn Furr, Michelle L. Lifton, Gail Levine, Steven Ma, Christopher Fletez-Brant, Wesley Hoyland, Madhu Prabhakaran, Sandeep Narpala, Kristin Boswell, Takuya Yamamoto, Hua-Xin Liao, David Pickup, Elizabeth Ramsburg, Laura Sutherland, Adrian McDermott, Mario Roederer, David Montefiori, Richard A. Koup, Barton F. Haynes, Norman L. Letvin, Sampa Santra   +23 more
doaj   +1 more source